NHS Lothian and Nucleix Presented Data at EAU25 Showcasing Potential of Bladder EpiCheck® to Improve Detection of Disease Recurrence in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients
EDINBURGH, Scotland & SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–NHS Lothian, Scotland’s second largest health authority providing a comprehensive range of primary, community-based and acute hospital services, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from an abstract featuring Nucleix’s Bladder EpiCheck® test presented at the 46th Annual European Association of Urology (EAU) Congress.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.